Better High-Yield Dividend Stock: Pfizer vs. Merck
Investors looking for ways to pump up their passive income streams might want to turn their heads toward the pharmaceutical industry. At recent prices, you can buy shares of (NYSE: MRK) that offer a yield above 3%, and shares of Pfizer (NYSE: PFE) offer a yield above 6%.
Which of these two high-yield dividend payers is best for your portfolio? Let's weigh their strong points against some of the challenges they face, to see which stock is a better buy now.
Shares of Merck have fallen about 34% from a peak they reached last year. The stock is under pressure because its lead drug, a cancer immunotherapy called Keytruda, is expected to lose patent-protected market exclusivity in the U.S. and Chinese markets in 2028.
Source Fool.com
Merck KGaA Stock
€117.10
-0.510%
Currently there is a rather positive sentiment for Merck KGaA with 4 Buy predictions and 0 Sell predictions.
With a target price of 142 € there is a positive potential of 21.26% for Merck KGaA compared to the current price of 117.1 €.
